References
- Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532–43.
- Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al.. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911–8.
- Ravandi F, O’Brien S, Thomas D, Faderl S, Jones D, Garris R, et al.. First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lympoblastic leukemia. Blood. 2010;116:2070–7.
- Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al.. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–80.
- Hoelzer D, Goekbuget N, Beck J, Burmeister T, Giagounidis A, Glasmacher A, et al.. Sub-type adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL). Blood. 2004;104:abstract 2732.
- Thomas D, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al.. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de-novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880–9.
- Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al.. Immunochemotherapy with rituximab improves molecular CR-rate and outcome in CD20+ B-lineage standard and high risk patients: results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood. 2010;116:abstract 170.
- Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al.. Targeted therapy with the T-cell-engaging antibody Blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–8.
- Topp MS, Goekbuget N, Zugmaier G, Viardot A, Stelljes M, Neumann S, et al.. Anti-CD19 BiTE Blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing Phase II trial. Blood (ASH Annual Meeting Abstracts). 2011;118:252.
- Kantarjian H, Thomas D, Jabbour E, Jorgensen J, Kabriaei P, Rytting M, et al.. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calecheamicin, shows significant antileukemic activity in patients with refractory-relapse acute lymphocytic leukemia. Lancet Oncol. 2011; to be published.
- Wayne A, Bhojwani D, Silverman LB, Kelly R, Stetler-Stevenson M, Shah N, et al.. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts). 2011;118:Abstract 248.